Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease

计划入组 40 人 · 首次发布于 2025 年 3 月 14 日

DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease

计划入组 16 人 · 首次发布于 2021 年 9 月 5 日

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

计划入组 79 人 · 首次发布于 2025 年 7 月 10 日

Colorectal cancer vaccine (Oryx)

Colorectal Cancer(Envisagenics)

Colorectal Cancer(Dewpoint)

Austrian Breast & Colorectal Cancer Study Group

Austria

OSAKA CENTER FOR CANCER AND CARDIOVASCULAR DISEASE PREVENTION

Japan

BORDEAUX COLORECTAL INSTITUTE ACADEMY

France

TAS-102 Shows Promise in Clearing Circulating Tumor DNA in Colorectal Cancer Patients with Minimal Residual Disease

AmMax Bio Doses First Patient in Phase 2a Trial of AMB-066 for Colorectal Cancer MRD

TransCode Therapeutics Advances TTX-MC138 to Phase 2a Trial for Minimal Residual Disease in Colorectal Cancer